United Therapeutics Corporation $UTHR Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 17.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 119,235 shares of the biotechnology company’s stock after selling 24,389 shares during the period. Hsbc Holdings PLC’s holdings in United Therapeutics were worth $70,617,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter valued at $31,000. Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new stake in United Therapeutics during the 4th quarter worth about $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on UTHR. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $644.82.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $535.67 on Monday. The stock has a market capitalization of $22.74 billion, a price-to-earnings ratio of 19.77, a PEG ratio of 1.79 and a beta of 0.58. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock has a 50-day moving average of $552.38 and a 200 day moving average of $530.33.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the company posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $576.93, for a total transaction of $5,769,300.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,890,130.68. This trade represents a 34.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 545,243 shares of company stock worth $305,155,272. Corporate insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.